{"nctId":"NCT01552694","briefTitle":"Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation","startDateStruct":{"date":"2012-10"},"conditions":["Inflammation","Macrophage Infiltration","Cardiovascular Disease"],"count":38,"armGroups":[{"label":"Sitagliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Sitagliptin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Sitagliptin","otherNames":["Januvia"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 18-65 yr old HIV infected men and women.\n* Stable (at least the past 6 months) on combined antiretroviral therapy (cART).\n* Stable immune (\\> 300 CD4+ T-cells/µL) and virologic (\\< 50 copies HIV RNA/mL) status.\n* Insulin resistant/impaired glucose tolerance (fasting glucose 100-125mg/dL, or 2-hr glucose 140-200mg/dL or fasting HOMA-IR= 2.5-6.0).\n* Waist circumference \\> 102 cm (men), \\> 88 cm (women).\n* BMI \\> 20 kg/m2.\n* Fasting hypertriglyceridemia \\> 150 mg/dL.\n* Low HDL-cholesterol (\\< 40 mg/dL in men or \\< 50 mg/dL in women).\n* Platelet count \\> 30,000/mm3.\n* Absolute neutrophil count \\> 750/mm3.\n* Transaminases \\< 2.5x the upper limit of normal.\n* Long-term non-progressors (not taking anti-HIV medications) are not eligible.\n\nExclusion Criteria:\n\n* Diabetes (T2DM, IDDM or diabetic ketoacidosis) or taking any glucose-lowering medication (e.g., insulin, TZDs, metformin, sulfonylurea).\n* Any agent that might artifactually alter glycemic control (e.g., glucocorticoids, megace, rhGH, GH-secretagogue, testosterone derivatives, creatine monohydrate, chromium picolinate, AA/protein supplements, medium- or long-chain fatty acids) during 6 months prior to or during enrollment.\n* History of serious CV disease. NYHA Functional Class III or IV (e.g., recent MI, unstable angina, edema, CHF, CAD, CABG, stroke, resting hypertension \\> 160/95 mmHg), irregular heart rhythm, resting ST-segment depression \\> 1mm). Treatment with medications for CV condition (e.g., α- or ß-blockers). Some BP-lowering medications (Ca++channel blocker, diuretic, or ACE inhibitor) are permitted.\n* Moderate to severe renal insufficiency. Serum creatinine \\> 1.7 mg/dL (men) \\> 1.5 mg/dL (women).\n* Plan or anticipate a change in anti-HIV medications during the study.\n* Lipid-lowering medications are permitted (fibrate or statin or niacin), but must be stable on that agent for at least 6 months prior to enrollment. Lipid-lowering agents cannot be started during the treatment period.\n* Chronic hepatitis B (HBV-surface antigen positive). Active hepatitis C (detectable Hep C RNA).\n* Positive urine drug test for opiates, methamphetamine, heroin, cocaine. Active substance abuse that the MD-scientist believes may compromise safety, compliance, interfere with study drug or data interpretation.\n* Hematocrit \\< 34% in men or \\< 25% in women with symptoms (fatigue, \"tired-legs\", shortness of breath). Hemoglobin \\< 10 gm/dL with symptoms.\n* Pregnant or nursing mothers. Women must agree to use an acceptable form of birth control during the study. If using birth control pills-must be stable on this medication for at least 6 months prior to enrollment.\n* Active malignancy or treatment with chemotherapeutic agents or radiation therapy or any cytokine or anti-cytokine therapy during 6 months prior to enrollment.\n* History of pancreatitis\n* \\> 10% unintentional weight loss during the 6 months prior to enrollment.\n* Reduced cognitive function/unable to provide voluntary informed consent. Prisoners are excluded.\n* Blinded investigational drugs for 3 months prior to enrollment that will not be unblinded before enrollment.\n* Nausea, vomiting, diarrhea (\\> 4 loose stools/day) that are unresponsive to treatment.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Inflammatory Biomarker 1: Plasma hsCRP Concentration","description":"Fasting serum and plasma samples obtained at baseline and week 8 are batched for ELISA analysis (end of sudy) of hsCRP, IL-6 and D-dimer concentrations.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"3.2"},{"groupId":"OG001","value":"5.4","spread":"4.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"2.6"},{"groupId":"OG001","value":"7.4","spread":"5.8"}]}]}]},{"type":"PRIMARY","title":"Inflammatory Biomarker 2: Plasma IL-6 Concentration","description":"There are 3 levels of the primary outcome measure; hsCRP, IL-6, and D-dimer concentrations measured at baseline and week 8","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.36","spread":"0.74"},{"groupId":"OG001","value":"2.61","spread":"1.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.30","spread":"0.55"},{"groupId":"OG001","value":"2.65","spread":"1.83"}]}]}]},{"type":"PRIMARY","title":"Inflammatory Biomarker 3: Serum D-dimer Concentration","description":"There are 3 levels of the primary outcome measure, hsCRP, IL-6, and D-dimer","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.32","spread":"0.20"},{"groupId":"OG001","value":"0.28","spread":"0.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"0.24"},{"groupId":"OG001","value":"0.31","spread":"0.20"}]}]}]},{"type":"SECONDARY","title":"Fold Change in Adipose Inflammation Marker CCL2 (MCP-1) mRNA Expression","description":"Adipose tissue from obese, insulin resistant subjects is characterized by increased macrophage infiltration and overexpression of inflammatory cytokines/chemokines. In adipose samples, mRNA expression for the macrophage inflammation marker CCL2 (MCP-1) was quantified. Fold change between population averages from baseline to 2 months for adipose macrophage CCL2 (MCP-1) mRNA expression is the outcome measure.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":null},{"groupId":"OG001","value":"-0.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Blood Endothelial Progenitor Cells","description":"Monocytes (PBMC) are isolated from 20 mL blood. CD34+/VEGFR2+/KDR+ monocytes represent cell markers for endothelial progenitor cells (EPC). CD34+/VEGFR2+/KDR+ monocytes are counted (flow cytometry) and expressed as a percentage of PBMC number. Percent change between population averages from baseline to 2 months for the EPC/PBMC ratio is calculated and reported as the outcome measure.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"-0.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":18},"commonTop":["Fatique, Fever, Chills, Loss of appetite, Weight Loss","Abdominal pain, nausea, vomiting, constipation, diarrhea, hypoglycemia","muscle ache, arthritis, swelling, weakness","headaches, dizziness ,numbness, depression, anxiety, confusion","Chest pain, shortness of breath, wheezing, cough"]}}}